Symbiotec Pharmalab Limited
NSE: SYMBIOTEC · Pharmaceuticals
Snapshot
Unlock Symbiotec Pharmalab Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Symbiotec Pharmalab Limited is a research-driven pharmaceutical company specialising in corticosteroid and steroidal-hormone active pharmaceutical ingredients. The company operates across organic chemistry, biotechnology, and complex injectables platforms with a backward-integrated microbe-to-pharmacy model.
Business Model
The company operates as a contract development and manufacturing organisation, generating revenue by supplying a diverse portfolio of APIs and complex injectables to global customers.
- Global Volume Market Share (Corticosteroids):38.2%
- Global Volume Market Share (Steroidal-hormone APIs):23.8%
- API Portfolio:>60 APIs
- Global Reach:>200 customers across >40 countries
Growth Outlook
Growth is driven by expanded manufacturing capacities in chemical synthesis, fermentation, and complex injectables, alongside strong regulatory compliance supporting global market penetration.
- Chemical Synthesis Capacity:584.67 metric tonnes
- Fermentation Capacity:700 kilolitres
- Complex Injectables Capacity:20 million vials per annum
- US FDA Drug Master Files:43 registered
Key Risks
- Regulatory Compliance Risk. Operations are subject to stringent inspections by global regulatory bodies such as the US FDA and EU-GMP, where any non-compliance could disrupt manufacturing and export activities.
- Concentration Risk. The company's significant reliance on corticosteroid and steroidal-hormone APIs exposes its revenue streams to market fluctuations within this specific therapeutic segment.
Start your research today
Unlock AI insights, financials, peers and live data on Symbiotec Pharmalab Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Symbiotec Pharmalab LimitedSYMBIOTEC | ₹6,824 Cr | — | — | — | 27.0% | — | — | — |
Sanofi India LimitedSANOFI | ₹7,030 Cr | 21.6× | 13.32 | -8.9% | 27.7% | 40.3% | 52.8% | -35.4% |
Morepen Laboratories LimitedMOREPENLAB | ₹6,704 Cr | 52.2× | 33.32 | 9.5% | 10.6% | 11.7% | 14.4% | +174.0% |
Sun Pharma Advanced Research Company LimitedSPARC | ₹6,673 Cr | 4.0× | 4.40 | 2855.8% | 86.0% | 282.4% | 235.1% | +46.9% |
Jeena Sikho Lifecare LimitedJSLL | ₹6,517 Cr | 25.3× | 16.91 | — | 45.2% | 50.6% | 58.2% | -40.8% |
Senores Pharmaceuticals Ltd.SENORES | ₹6,371 Cr | 47.5× | 28.38 | — | 34.7% | 15.2% | 18.4% | +88.6% |
As of Mar 2026
Financials
Symbiotec Pharmalab Limited
NSE: SYMBIOTEC · Pharmaceuticals
Snapshot
Unlock Symbiotec Pharmalab Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Symbiotec Pharmalab Limited is a research-driven pharmaceutical company specialising in corticosteroid and steroidal-hormone active pharmaceutical ingredients. The company operates across organic chemistry, biotechnology, and complex injectables platforms with a backward-integrated microbe-to-pharmacy model.
Business Model
The company operates as a contract development and manufacturing organisation, generating revenue by supplying a diverse portfolio of APIs and complex injectables to global customers.
- Global Volume Market Share (Corticosteroids):38.2%
- Global Volume Market Share (Steroidal-hormone APIs):23.8%
- API Portfolio:>60 APIs
- Global Reach:>200 customers across >40 countries
Growth Outlook
Growth is driven by expanded manufacturing capacities in chemical synthesis, fermentation, and complex injectables, alongside strong regulatory compliance supporting global market penetration.
- Chemical Synthesis Capacity:584.67 metric tonnes
- Fermentation Capacity:700 kilolitres
- Complex Injectables Capacity:20 million vials per annum
- US FDA Drug Master Files:43 registered
Key Risks
- Regulatory Compliance Risk. Operations are subject to stringent inspections by global regulatory bodies such as the US FDA and EU-GMP, where any non-compliance could disrupt manufacturing and export activities.
- Concentration Risk. The company's significant reliance on corticosteroid and steroidal-hormone APIs exposes its revenue streams to market fluctuations within this specific therapeutic segment.
Start your research today
Unlock AI insights, financials, peers and live data on Symbiotec Pharmalab Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026